Sugi Predict

Sugi Predict / Compounds / SCHEMBL1006804

SCHEMBL1006804

SCHEMBL1006804

CS(=O)(=O)c1ccc(Br)c(N)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ G6PD P11413 1/20 0.53
▸ IDE P14735 1/20 0.53
▸ CA2 P00918 7/20 0.48
▸ CA1 P00915 6/20 0.48
▸ CA9 Q16790 6/20 0.48
▸ CA12 O43570 5/20 0.48
▸ CA4 P22748 4/20 0.48
▸ CA6 P23280 4/20 0.48
▸ CA5A P35218 4/20 0.48
▸ CA7 P43166 4/20 0.48
▸ CA14 Q9ULX7 4/20 0.48
▸ CA5B Q9Y2D0 4/20 0.48
▸ GAA P10253 2/20 0.42
▸ MAPT P10636 2/20 0.42
▸ PKM P14618 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ ALDH1A1 P00352 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10694524 0.83 CA2 (0.70) G6PDIDECA2CA1CA9
SCHEMBL29948313 0.83 CA2 (0.70) G6PDIDECA2CA1CA9
SCHEMBL4603717 0.83 CA2 (0.69) CA2CA1CA9CA12CA4
SCHEMBL898422 0.80 G6PD (0.64) G6PDIDECA2CA1CA9
SCHEMBL29826051 0.80 GAA (0.52) CA2CA1CA9CA12CA4
SCHEMBL8911366 0.79 ALDH1A1 (0.62) CA2CA1CA9CA12CA4
SCHEMBL7956783 0.78 G6PD (0.52) G6PDIDECA2CA1CA9
SCHEMBL29421567 0.77 LMNA (0.49) G6PDIDEMAPTMEN1KMT2A
SCHEMBL4639254 0.77 G6PD (0.60) G6PDIDECA2CA1CA9
SCHEMBL1368132 0.77 G6PD (0.55) G6PDIDECA2CA1CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304537-A1 HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME REPARE THERAPEUTICS INC. (CA) 2025-10-02 — — US disclosed
US-12377084-B2 ERAP1 modulators Grey Wolf Therapeutics Limited (GB) 2025-08-05 — — US disclosed
CN-119894872-A Heteroarenes, pharmaceutical compositions containing heteroarenes, and methods of use thereof 修复治疗公司 2025-04-25 — — CN disclosed
EP-4526293-A1 HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME Repare Therapeutics Inc. (CA) 2025-03-26 — — EP disclosed
US-20240383870-A1 HETEROCYCLIC ALDEHYDE TRAPPING COMPOUNDS AND USES THEREOF ALDEYRA THERAPEUTICS, INC. 2024-11-21 — — US disclosed
US-20240366595-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2024-11-07 — — US disclosed
US-12023333-B2 Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators Grey Wolf Therapeutics Limited (GB) 2024-07-02 — — US disclosed
EP-4362930-A1 HETEROCYCLIC ALDEHYDE TRAPPING COMPOUNDS AND USES THEREOF Aldeyra Therapeutics, Inc. (US) 2024-05-08 — — EP disclosed
CN-117580569-A Heterocyclic aldehyde capture compounds and uses thereof 奥尔德拉医疗公司 2024-02-20 — — CN disclosed
WO-2023220831-A1 HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME REPARE THERAPEUTICS INC. (CA) 2023-11-23 — — WO disclosed
EP-2558069-A1 BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF Novartis AG (CH) 2013-02-20 — — EP disclosed
EP-2512478-A1 HOMOGENEOUS SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOF Novartis AG (CH) 2012-10-24 — — EP disclosed
US-20120263753-A1 BENZONAPHTHYRIDINE-CONTAINING VACCINES NOVARTIS AG (CH) 2012-10-18 — — US disclosed
EP-2440245-A1 BENZONAPHTHYRIDINE-CONTAINING VACCINES Novartis AG (CH) 2012-04-18 — — EP disclosed
WO-2011130379-A1 BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF NOVARTIS AG (CH) 2011-10-20 — — WO disclosed
WO-2011084549-A1 HOMOGENEOUS SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2011-07-14 — — WO disclosed
US-20110081365-A1 COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS IRM LLC (BM) 2011-04-07 — — US disclosed
EP-2268618-A1 COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS IRM LLC (BM) 2011-01-05 — — EP disclosed
WO-2010144734-A1 BENZONAPHTHYRIDINE-CONTAINING VACCINES NOVARTIS AG (CH) 2010-12-16 — — WO disclosed
WO-2009111337-A1 COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS IRM LLC (BM) 2009-09-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366595-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS CHP1, ERAP1, QSOX1 G6PD 1793/4885IDE 2948/4885CA2 596/4885
US-20250304537-A1 HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME CSNK1A1, CSNK1G1, CSNK2A1 G6PD 1051/4885IDE 4447/4885CA2 1642/4885
US-12377084-B2 ERAP1 modulators ERAP1, NR1I3, HRH4 G6PD 1459/4885IDE 4028/4885CA2 434/4885
US-20120263753-A1 BENZONAPHTHYRIDINE-CONTAINING VACCINES LY96, TLR3, GABRA4 G6PD 3821/4885IDE 1757/4885CA2 3008/4885
US-12023333-B2 Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators ERAP1, CHP1, QSOX1 G6PD 1620/4885IDE 3233/4885CA2 453/4885
US-20110081365-A1 COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS TLR5, TLR8, TLR7 G6PD 2594/4885IDE 3976/4885CA2 2572/4885
US-20240383870-A1 HETEROCYCLIC ALDEHYDE TRAPPING COMPOUNDS AND USES THEREOF ALDH1A2, ALDH2, SSB G6PD 1303/4885IDE 4176/4885CA2 252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.